Help to accelerate the development of small molecule therapeutics against lupus erythematosus through licensing or direct investment.
The treatment is based on a novel targeting strategy for stopping autoimmunity in patients.
The treatment is
Systemic lupus erythematosus is a debilitating and chronic autoimmune disease affecting more than five million people worldwide. Efficacy rates of current treatments are modest, and some deplete beneficial B-cells, greatly weakening the immune system and increasing risk of infections. On top of this, state-of-the-art treatments are
Studies have identified a unique targeting approach based on selectively removing a highly inflammatory component of B-cell activating factor that is differential to the BAFF targeting approaches that are currently in the market or in development.
A biomarker to stratify patients for disease severity and the pathogenic mechanism has also been identified, enabling relevant subgroup targeting in clinical trials.
Download flyer for more information (PDF)
Negotiating a licence with the University
By licensing the University of Melbourne’s intellectual property (IP) and technologies, you can harness research discoveries to solve business challenges.
Our IP principles
Our Intellectual Property (IP) management principles make it easier to collaborate with us.
Investing in University startups
Find out about new ways to invest in University startups
From developing an idea to finding startup funding, the University of Melbourne’s team of experts can help.